Sight Sciences, Inc. (NASDAQ:SGHT - Get Free Report) CEO Paul Badawi sold 23,637 shares of the company's stock in a transaction on Tuesday, July 1st. The shares were sold at an average price of $4.15, for a total transaction of $98,093.55. Following the completion of the sale, the chief executive officer directly owned 5,986,943 shares in the company, valued at approximately $24,845,813.45. This represents a 0.39% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link.
Sight Sciences Stock Performance
NASDAQ SGHT traded up $0.08 during trading hours on Tuesday, reaching $3.55. 166,363 shares of the company were exchanged, compared to its average volume of 212,899. Sight Sciences, Inc. has a 1 year low of $2.03 and a 1 year high of $8.45. The business's 50 day simple moving average is $3.71 and its 200-day simple moving average is $3.13. The company has a quick ratio of 9.99, a current ratio of 10.47 and a debt-to-equity ratio of 0.51. The stock has a market capitalization of $183.54 million, a P/E ratio of -3.62 and a beta of 2.47.
Sight Sciences (NASDAQ:SGHT - Get Free Report) last issued its earnings results on Thursday, May 8th. The company reported ($0.28) earnings per share for the quarter, topping analysts' consensus estimates of ($0.29) by $0.01. The firm had revenue of $17.51 million during the quarter, compared to analyst estimates of $16.51 million. Sight Sciences had a negative net margin of 63.24% and a negative return on equity of 54.62%. On average, equities research analysts expect that Sight Sciences, Inc. will post -0.99 earnings per share for the current year.
Hedge Funds Weigh In On Sight Sciences
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Charles Schwab Investment Management Inc. lifted its holdings in shares of Sight Sciences by 4.4% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 268,250 shares of the company's stock worth $976,000 after buying an additional 11,259 shares in the last quarter. WealthTrust Asset Management LLC purchased a new stake in shares of Sight Sciences in the fourth quarter worth about $48,000. American Century Companies Inc. lifted its holdings in shares of Sight Sciences by 10.7% in the fourth quarter. American Century Companies Inc. now owns 51,564 shares of the company's stock worth $188,000 after buying an additional 4,964 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. purchased a new stake in shares of Sight Sciences in the fourth quarter worth about $50,000. Finally, JPMorgan Chase & Co. lifted its holdings in shares of Sight Sciences by 52.7% in the fourth quarter. JPMorgan Chase & Co. now owns 106,351 shares of the company's stock worth $387,000 after buying an additional 36,691 shares in the last quarter. Institutional investors own 55.51% of the company's stock.
Analysts Set New Price Targets
Several analysts have recently commented on SGHT shares. Lake Street Capital increased their target price on shares of Sight Sciences from $2.50 to $3.00 and gave the company a "hold" rating in a report on Friday, May 9th. Needham & Company LLC reiterated a "hold" rating on shares of Sight Sciences in a report on Wednesday, April 9th. Wall Street Zen upgraded shares of Sight Sciences from a "sell" rating to a "hold" rating in a report on Saturday, June 28th. Piper Sandler reiterated a "neutral" rating and issued a $4.00 target price (up previously from $3.50) on shares of Sight Sciences in a report on Wednesday, June 18th. Finally, Citigroup restated a "neutral" rating and set a $3.60 price objective (up previously from $3.20) on shares of Sight Sciences in a report on Thursday, May 22nd. Six equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company's stock. According to data from MarketBeat.com, Sight Sciences has a consensus rating of "Hold" and an average price target of $4.10.
Read Our Latest Analysis on Sight Sciences
Sight Sciences Company Profile
(
Get Free Report)
Sight Sciences, Inc, an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.
Recommended Stories
Before you consider Sight Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sight Sciences wasn't on the list.
While Sight Sciences currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
